Edesa Biotech, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported net loss was USD 8.37 million compared to USD 17.55 million a year ago. Basic loss per share from continuing operations was USD 2.93 compared to USD 8.37 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.435 USD | -3.80% | -1.00% | -2.95% |
05-10 | Edesa Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
03-05 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.95% | 14.83M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- EDSA Stock
- News Edesa Biotech, Inc.
- Edesa Biotech, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023